// App-Quantinova.ai

TPS5071 : A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-nave metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Gerhardt Attard

  • Mary Beth Todd

  • Daphne Wu

  • Thian Kheoh

  • Xin Zhao

  • Fred Saad

  • Eleni Efstathiou

  • Margaret K. Yu

  • Thomas W. Griffin

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United KingdomJanssen Research & Development, San Francisco, CAJanssen Research & Development, Los Angeles, CA

  • Janssen Global Services, Raritan, NJ

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • ARN-509

  • Epimorph

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • randomized

Phase

  • III

Study Id's

  • NCT02257736

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved